Polymeric human Fc-fusion proteins with modified effector functions

Scientific Reports

Volumn 1, Issue , 2011, Pages

  Mekhaiel, David N A ^a   Czajkowsky, Daniel M ^b,c   Andersen, Jan Terje ^d   Shi, Jianguo ^a   El Faham, Marwa ^e,f   Doenhoff, Michael ^e   McIntosh, Richard S ^e   Sandlie, Inger ^d   He, Jianfeng ^c   Hu, Jun ^b   Shao, Zhifeng ^c   Pleass, Richard J ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b SHANGHAI INSTITUTE OF APPLIED PHYSICS   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^f ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; FC RECEPTOR; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; PRIMER DNA;

ANIMAL; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; BIOLOGICAL THERAPY; CHEMICAL STRUCTURE; CHEMISTRY; FEMALE; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; MALARIA; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; PARASITOLOGY; PLASMODIUM BERGHEI; PROTEIN BINDING; PROTEIN MULTIMERIZATION;

ANIMALS; B-LYMPHOCYTES; BASE SEQUENCE; BIOLOGICAL THERAPY; COMPLEMENT SYSTEM PROTEINS; DNA PRIMERS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MALARIA; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; PLASMODIUM BERGHEI; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTORS, FC; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS;

EID: 84859760033     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00124     Document Type: Article

References (57)

1. Strohl, W. R, Knight, D. M. Discovery and development of biopharmaceuticals: current issues. Curr Opin Biotech 20, 668-672 (2009).
2. Huang, C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODYTM technology. Curr Opin Biotech 20, 692-699 (2009).
3. Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7, 715-25 (2007). (Pubitemid 47327396)
4. Vaccaro, C., Bawdon, R., Wanjie, S., Ober, R. J. & Ward, E. S. Divergent activities of an engineered Ab in murine and human systems have implications for therapeutic Abs. Proc Natl Acad Sci USA 103, 18709-14 (2006). (Pubitemid 44913475)
5. Nimmerjahn, F. & Ravetch, J. V. Fc-receptors as regulators of immune responses. Nat Rev Immunol 8, 34-47 (2008).
6. Nimmerjahn, F. & Ravetch, J. V. Fc-receptors as regulators of immunity. Adv Immunol 96, 179-204 (2007). (Pubitemid 350018720)
7. Nimmerjahn, F. & Ravetch, J. V. FccRs in health and disease. Curr Top Microbiol Immunol 350, 105-25 (2011).
8. Regnault, A. et al. Fcc-receptor-mediated induction of dendritic cell maturation and MHC class I restricted Ag presentation after immune complex internalization. J Exp Med 189, 371-80 (1999). (Pubitemid 29063258)
9. Dhodapkar, K. M., Krasovsky, J., Williamson, B., Dhodapkar, M. V. Antitumour monoclonal Abs enhance cross-presentation of cellular Ags and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195, 125-33 (2002). (Pubitemid 34074502)
10. Groh, V. et al. Efficient cross-priming of tumour Ag-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumour cells. Proc Natl Acad Sci USA 102, 6461-66 (2005). (Pubitemid 40617465)
11. Rafiq, K., Bergtold, A. & Clynes, R. Immune complex-mediated Ag presentation induces tumor immunity. J Clin Invest 110, 71-9 (2002). (Pubitemid 34743467)
12. Schuurhuis, D. H, et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol 176, 4573-80 (2006).
13. Baker, K. et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune-complexes by CD8-CD11b1dendritic cells. Proc Natl Acad Sci USA 108, 9927-32 (2011).
14. Bergtold, A., Desai, D. D., Gavhane, A. & Clynes, R. Cell surface recycling of internalized Ag permits dendritic cell priming of B cells. Immunity 23, 503-14 (2005). (Pubitemid 41587890)
15. Kalergis, A. M. & Ravetch, J. V. Inducing tumor immunity through the selective engagement of activating Fcc-receptors on dendritic cells. J Exp Med 195, 1653-59 (2002). (Pubitemid 34666079)
16. Boruchov, A. M. et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 115, 2914-23 (2005). (Pubitemid 41434419)
17. Dhodapkar, K. M. et al. Selective blockade of inhibitory Fcg-receptor enables human dendritic cell maturation with IL-12p70 production and immunity to Abcoated tumor cells. Proc Natl Acad Sci USA 102, 2910-15 (2005). (Pubitemid 40299890)
18. Smith, R. I., Coloma, M. J. & Morrison, S. L. Addition of a mu-tailpiece to IgG results in polymeric Abswith enhanced effector functions including complementmediated cytolysis by IgG4. J Immunol 154, 2226-36 (1995).
19. Soerensen, V., Sundvold, T. E., Michaelsen, T. E. & Sandlie, I. Polymerization of IgA and IgM: roles of Cys309/Cys414 and the secretory tailpiece. J Immunol 162, 3448-55 (1999). (Pubitemid 29313595)
20. Ghumra, A. et al. Identification of residues in the Cm4 domain of polymeric IgM essential for interaction with Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1).J Immunol 181, 1988-2000 (2008).
21. Czajkowsky, D. M. & Shao, Z. The human IgM pentamer is a mushroom-shaped molecule with a flexural bias. Proc Natl Acad Sci USA 106, 14960-65 (2009).
22. Andersen, J. T., Daba, M. B., Berntzen, G., Michaelsen, T. E. & Sandlie, I. Crossspecies binding analyses of mouse and human neonatal Fc receptor show dramatic differences in IgG and albumin binding. J Biol Chem 285, 4826-36 (2010).
23. Doenhoff, M. J. A vaccine for schistosomiasis: alternative approaches. Trends Parasitol 14, 105-9 (1998). (Pubitemid 28101507)
24. Woof, J. M., Partridge, L. J., Jefferis, R. & Burton, D. R. Localization of the monocyte-binding region on human immunoglobulin G. Mol Immunol 23, 319-30 (1986). (Pubitemid 16128895)
25. Woof, J. M. & Burton, D. R. Human Ab-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 4, 89-99 (2004). (Pubitemid 38209203)
26. Bruhns, P. et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716-25 (2009).
27. Gaboriaud, C. et al. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J Biol Chem 278, 46974-82 (2003). (Pubitemid 37452280)
28. Wu, A. M. & Senter, P. D. Arming Abs: prospects and challenges for immunoconjugates. Nat Biotech 23, 1137-46 (2005). (Pubitemid 41486395)
29. Orange, J. S. et al. Use of intravenous immunoglobulin in human disease: a review of eviodence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117, S525-53.
30. Debre M et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342, 945-9 (1993). (Pubitemid 23305497)
31. Samuelsson, A., Towers, T. L. & Ravetch, J. V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291, 484-6 (2001). (Pubitemid 32097072)
32. Bazin, R. et al. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal Ab. Br J Haematol 135, 97-100 (2006). (Pubitemid 44337669)
33. Crow, A. R. et al. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102, 558-60 (2003). (Pubitemid 36841975)
34. Leontyev, D. et al. The inhibitory Fcc receptor is unecessary for IVIG efficacy. Nature Preceedings. http://precedings. nature. com/documents/4635/ version/1 (2010)
35. Araujo, L. M. et al. Intravenous Ig inhibits invariant NKT cell-mediated allergic airway inflammation through FcgRIIIA-dependent mechanisms. J Immunol 186, 3289-93 (2011).
36. Machino, Y. et al. Effect of IgG interchain disulfide bond cleavage on efficacy of IVIg for immune thrombocytopenic purpura (ITP).Clin Exp Immunol. 162, 415-24 (2010).
37. Anthony, R. M. et al. Identification of a receptor required for the antiinflammatory activity of IVIG. Proc Natl Acad Sci USA 105, 19571-78 (2008).
38. Sé̈te J. F. et al. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 116, 1698-704 (2010).
39. Anthony, R. M., Kobayashi, T., Wermeling, F. & Ravetch, J. V. Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway. Nature 475, 110-116 (2011).
40. Roux, K. H. & Tankersley, D. L. Aview of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimmers in pooled human IgG. J Immunol 144, 1387-95 (1990). (Pubitemid 20072911)
41. Yoo, E. M., Wims, L. A., Chan, L. A. & Morrison, S. L. Human IgG2 can form covalent dimmers. J Immunol 170, 3134-8 (2003). (Pubitemid 36302189)
42. Schneider-Merck, T. et al. Human IgG2 Abs against epidermal growth factor receptor effectively trigger Ab-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of the myeloid lineage. J Immunol 512-20 (2010).
43. Nezlin, R. Circulating non-immune IgG complexes in health and disease. Immunol Lett 122, 141-4 (2009).
44. Nimmerjahn, F. & Ravetch, J. V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310, 1510-2 (2005). (Pubitemid 41746349)
45. Price, H. P., Doenhoff, M. J. & Sayers, J. R. Cloning, heterologous expression and Agicity of a schistosome cercarial protease. Parasitology 114, 447-53 (1997). (Pubitemid 27210013)
46. Lewis, M. J., Wagner, B. & Woof, J. M. The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies. Mol Immunol 45, 818-27 (2008). (Pubitemid 47498575)
47. Pizarro, J. C. et al. Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment ofmerozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate. J Mol Biol 328, 1091-103 (2003). (Pubitemid 36506876)
48. Deisenhofer, J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2. 9-and 2. 8-A resolution. Biochemistry 20, 2361-70 (1981). (Pubitemid 11089772)
49. Humphrey, W., Dalke, A., Schulten, K. VMD: visual molecular dynamics. J Mol Graph 14, 27-38 (1986).
50. Phillips, J. C. et al. Scalable molecular dynamics with NAMD. J Comput Chem 26, 1781-802 (2005). (Pubitemid 43078511)
51. MacKerell, A. D., et al. All atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102, 3586-616 (1998).
52. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. J Chem Phys 79, 926-935 (1983).
53. Guex, N. & Peitsch, M. C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative modeling. Electrophoresis 18, 2714-23 (1997). (Pubitemid 28059943)
54. McIntosh, R. S. et al. The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathogens 18;3(5), e72 (2007).
55. Martin, W. L., West, A. P., Gan, L. & Bjorkman, P. J. Crystal structure at 2. 8Aof an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 7, 867-77 (2001). (Pubitemid 32436446)
56. Sauer-Eriksson, A. E., Kleywegt, G. J., Uhle, M., & Jones, T. A. Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure 3, 265-78 (1995).
57. Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. The 3. 2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406, 267-273 (2000). (Pubitemid 30604397)